Loading...
12 Asia Hyperglycemics Reports
Region Covered: Asia
Study Period: 2018 - 2029
Countries Covered: Japan, South Korea, China, India, Australia, Vietnam, Malaysia, Indonesia, Philippines, Thailand
Major Players: Eli Lilly, Boehringer Ingelheim, Janssen Pharmaceuticals, AstraZeneca, Bristol Myers Squibb
Region Covered: Asia
Study Period: 2019 - 2029
Countries Covered: Japan, South Korea, China, India, Australia, Vietnam, Malaysia, Indonesia, Philippines, Thailand
Major Players: Takeda, Bristol-Myers Squibb, Glenmark, Merck and Co., Sanofi Aventis
Region Covered: Asia
Study Period: 2019 - 2029
Countries Covered: Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, Thailand, Vietnam
Major Players: Novo Nordisk, Eli Lilly, Sanofi, Biocon, Gan & Lee
Region Covered: Asia
Study Period: 2018 - 2029
Countries Covered: Japan, China, South Korea, India, Australia, Malaysia, Indonesia, Philippines, Thailand
Major Players: Novo Nordisk, Glenmark, Novartis, Kissei, Biocon
Region Covered: Asia
Study Period: 2019- 2029
Countries Covered: United States, Canada, Germany, Spain, Italy, France, United Kingdom, Russia, Japan, China, Australia, India, South Korea, Malaysia, Indonesia, Thailand, Vietnam, Philippines, Brazil, Mexico, South Africa, Saudi Arabia, Oman, Egypt, Iran
Major Players: Glenmark Pharmaceuticals, Novartis, Kissei Pharmaceuticals, Biocon, Novo Nordisk A/S
Region Covered: Asia
Study Period: 2019 - 2029
Countries Covered: United States, Canada, France, Germany, Italy, Spain, United Kingdom, Russia, Mexico, Brazil, Japan, South Korea, China, India, Australia, Vietnam, Malaysia, Indonesia, Philippines, Thailand, Saudi Arabia, Iran, Egypt, Oman, South Africa
Major Players: Janssen Pharmaceuticals, Eli Lilly, Bristol Myers Squibb, AstraZeneca Pharmaceuticals, Astellas
Region Covered: Asia
Study Period: 2019 - 2029
Countries Covered: United States, Canada, Mexico, Germany, United Kingdom, France, Italy, Spain, China, Japan, India, Australia, South Korea, South Africa, Brazil, Argentina
Major Players: Abbott, Sanofi , Mylan Inc, Lupin, Aurobindo Pharma
Region Covered: Asia
Study Period: 2018 - 2029
Countries Covered: United States, Canada, France, Germany, Italy, Spain, United Kingdom, Russia, Mexico, Brazil, Japan, South Korea, China, India, Australia, Vietnam, Malaysia, Indonesia, Philippines, Thailand, Saudi Arabia, Iran, Egypt, Oman, South Africa
Major Players: Sanofi Aventis, Novo Nordisk AS, Biocon, Eli Lilly and Company, Julphar
Region Covered: Asia
Study Period: 2019 - 2029
Countries Covered: United States, Canada, Germany, Spain, Italy, France, United Kingdom, Russia, Japan, China, Australia, India, South Korea, Malaysia, Indonesia, Thailand, Philippines, Vietnam, Brazil, Mexico, South Africa, Saudi Arabia, Oman, Egypt, Iran
Major Players: Novo Nordisk, Sanofi, Eli Lilly, Biocon, Wockhardt
Region Covered: Asia
Study Period: 2019 - 2029
Countries Covered: United States, Canada, Mexico, Germany, United Kingdom, France, Italy, Spain, China, Japan, India, Australia, South Korea, South Africa, Brazil, Argentina
Major Players: Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., Sanofi, Biocon
Region Covered: Asia
Study Period: 2019- 2029
Countries Covered: United States, Canada, France, Germany, Italy, Spain, United Kingdom, Russia, Mexico, Brazil, Japan, South Korea, China, India, Australia, Vietnam, Malaysia, Indonesia, Philippines, Thailand, Saudi Arabia, Iran, Egypt, Oman, South Africa
Major Players: Sanofi Aventis, Pfizer Inc., Merck & Co., Inc., Torrent Pharma, Dr. Reddy's Laboratories
Region Covered: Asia
Study Period: 2018 - 2029
Countries Covered: United States, Canada, Germany, Spain, Italy, France, United Kingdom, Russia, Japan, China, Australia, India, South Korea, Malaysia, Indonesia, Thailand, Philippines, Vietnam, Brazil, Mexico, South Africa, Saudi Arabia, Oman, Egypt, Iran
Major Players: Bristol Myers Squibb, Glenmark Pharmaceuticals, Takeda, Sanofi Aventis, Merck and Co.
Filter Reports
By Countries
